Assessment of cell engineering strategies for improved therapeutic protein production in CHO cells.
Recombinant glycoprotein therapeutics have proven to be invaluable pharmaceuticals for the treatment of various diseases. Chinese hamster ovary (CHO) cells are widely used in industry for the production of these proteins. Several strategies for engineering CHO cells for improved protein production have been tried with considerable results. The focus has mainly been to increase the specific productivity and to extend the culture longevity by preventing programmed cell death. These CHO cell engineering strategies, particularly those developed in Korea, are reviewed here.
Mohan
Chaya
C
Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejon, Korea.
Kim
Yeon-Gu
YG
Koo
Jane
J
Lee
Gyun Min
GM
D000818:Animals; D016466:CHO Cells / Q000502:physiology*; D006224:Cricetinae; D003412:Cricetulus; D024861:Genetic Enhancement / Q000379:methods*; D015202:Protein Engineering / Q000379:methods*; D011994:Recombinant Proteins / Q000096:biosynthesis*; D013673:Technology Assessment, Biomedical
D011994:Recombinant Proteins